HNGE — Hinge Health, Inc.

Hinge Health Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $182 million, up 47% year-over-year (Q1 2025: $124 million), exceeding guidance of $171-$173 million.
• Calculated Billings: $770 million for the last 12 months, a 52% increase from $507 million in the prior year.
• Gross Margin: 85%, up from 81% in Q1 2025, reflecting operational efficiencies.
• Operating Income: $46 million, with a 25% operating margin, surpassing guidance of $30-$32 million.
• Free Cash Flow: $42 million, a significant increase from $4 million in Q1 2025, representing a 23% free cash flow margin.
• Share Repurchase: 2.5 million shares purchased for $105 million, reducing diluted share count by 2.5%.

2. Strategic Updates and Business Highlights

• New Product Launch: Introduction of a migraine care program, leveraging existing technology and infrastructure, with 125 clients adopting it, covering over 2 million eligible lives.
• Market Expansion: Focus on automating care delivery across multiple conditions, with migraine care seen as a significant growth opportunity.
• Sales Pipeline: Strong growth in the sales pipeline, particularly in the SMB segment, with a substantial increase in eligible lives from both new and existing clients.
• Hinge Select Program: Expansion in provider locations to 4,100, with positive momentum and integration into major health plans.

3. Forward Guidance and Outlook

• Q2 2026 Revenue Guidance: Expected to be between $194 million and $196 million, indicating a 40% year-over-year growth.
• Full Year 2026 Revenue Guidance: Raised to $798 million to $804 million, up from previous guidance of $732 million to $742 million, reflecting strong demand and growth in eligible lives.
• Operating Income Guidance: Increased to $205 million to $215 million for the full year, with a projected operating margin of 26%.

4. Bad News, Challenges, or Points of Concern

• Regulatory Caution: The company opted not to apply for the CMS ACCESS Model, citing concerns over clinical oversight and potential risks to vulnerable populations.
• Market Competition: While Hinge Health is seeing strong demand, the competitive landscape remains challenging, particularly in the digital health space where engagement and ROI are critical.
• Transition to New Pricing Models: Approximately 20% of clients remain on older subscription pricing, which may slow revenue growth from those accounts.

5. Notable Q&A Insights

• Migraine Program Viability: Clients are eager for the migraine program, recognizing the high costs associated with migraine care and the need for effective solutions.
• Yield Improvement: Current yields are slightly above 4%, with potential for further growth as new programs like migraine care are rolled out.
• Targeting Strategies: The company plans to leverage claims and pharmacy data to target potential migraine sufferers, similar to their approach for musculoskeletal care.
• Engagement Model Success: The engagement-based pricing model has proven effective, with higher member engagement and satisfaction compared to traditional models.

Overall, Hinge Health demonstrated strong financial performance in Q1 2026, with significant growth in revenue and profitability, while also laying the groundwork for future expansion into new healthcare areas like migraine care. The company remains optimistic about its growth trajectory, despite some regulatory and competitive challenges.